CareDx Reports Strong FY25 Results, $88M Share Repurchase, and Positive 2026 Guidance; Appoints New CFO

summarizeSummary

CareDx announced strong Q4 and full-year 2025 financial results, including an $88 million share repurchase, and issued positive 2026 guidance, alongside an internal CFO appointment.

check_boxKey Events

• Strong Full-Year 2025 Financial Performance

  Reported full-year 2025 revenue of $380 million, a 14% increase year-over-year, with Q4 2025 revenue up 25% to $108 million. Adjusted EBITDA for the full year was $32 million, up from $28 million in 2024.

• Significant Share Repurchase Program

  Completed $88 million in share repurchases during 2025, acquiring 5.8 million shares at an average price of $15.16 per share. This finalizes the program announced on 2026-01-12.

• Positive 2026 Financial Guidance

  Issued full-year 2026 revenue guidance in the range of $420 million to $444 million and adjusted EBITDA guidance between $30 million and $45 million, indicating continued growth.

• CFO Transition with Internal Promotion

  Nathan Smith resigned as CFO for personal reasons, effective February 25, 2026, with no disagreements cited. Keith Kennedy, the current Chief Operating Officer, was appointed as the new CFO and COO, effective February 26, 2026.

auto_awesomeAnalysis

CareDx, Inc. reported robust financial results for Q4 and full-year 2025, highlighted by significant revenue growth and a substantial $88 million share repurchase program. The company also provided optimistic revenue and adjusted EBITDA guidance for 2026, signaling continued growth. While the company recorded a GAAP net loss for the full year, the strong operational performance, cash flow, and capital return initiatives are positive indicators. The CFO transition was handled smoothly with an internal promotion, mitigating potential concerns.